Results 221 to 230 of about 57,494 (245)

Ultrasensitive and rapid colorimetric detection of paraquat via a high specific VHH nanobody.

Biosensors & bioelectronics, 2022
Rapid and quantitative detection of paraquat is crucial because of its high toxicity. Here, we developed an ultrasensitive time-resolved fluorescence immunochromatographic assay (TRFICA) strip based on our synthesized variable domain of heavy chain ...
Yongyi Zhang, Li-hua Li, Yu Wang, Hong Wang, Zhenlin Xu, Yuan-Xin Tian, Yuan-ming Sun, Jinyi Yang, Yu-Dong Shen   +8 more
semanticscholar   +1 more source

Quality assessment of VHH models

Journal of Biomolecular Structure and Dynamics, 2023
Heavy Chain Only Antibodies are specific to Camelid species. Despite the lack of the light chain variable domain, their heavy chain variable domain (VH) domain, named VHH or nanobody, has promising potential applications in research and therapeutic ...
A. Nadaradjane, J. Diharce, Joseph Rebehmed, F. Cadet, F. Gardebien, Jean-Christophe Gelly, C. Etchebest, A. D. de Brevern   +7 more
semanticscholar   +1 more source

Selection of VHHs Under Application Conditions

2012
The successful application of antibody fragments such as VHHs in diagnostic assays, affinity purification, imaging, or therapy is not determined by the specificity and affinity of the antibody fragment alone. The ability to bind the target protein in the environment in which the antibody fragment is intended to functionally perform determines to a ...
Dolk, E., Verrips, C.T., de Haard, J.J.W.   +2 more
openaire   +3 more sources

A disposable VHH-based SPR fiber probe for sensitive and specific detection of MMP-9 in cancer and inflammatory disease.

Biosensors & bioelectronics
A novel one-step label-free immunoassay platform was developed through the integration of nanobody (VHH) technology with a disposable surface plasmon resonance (SPR) fiber probe for rapid, precise biomarker detection.
Dandan Wu, Jian Yang, Junxiao Cong, Jian Zhou, Youbin Li, Feng Yan, Xuejin Li, Yuzhi Chen, Liang Ye   +8 more
semanticscholar   +1 more source

Developing drug-like single-domain antibodies (VHH) from in vitro libraries

mAbs
Here, we describe a new VHH library for therapeutic discovery which optimizes humanness, stability, affinity, diversity, developability, and facile purification using protein A in the absence of an Fc domain.
M. Erasmus, Andre A R Teixeira, Esteban Molina, Luis Antonio Rodriguez Carnero, Jianquan Li, David Knight, Roberto Di Niro, Camila Leal-Lopes, A. Fanni, Hallie Troell, Ashley DeAguero, Laura Spector, S. D’Angelo, F. Ferrara, A. R. Bradbury   +14 more
semanticscholar   +1 more source

Affinity‐stability trade‐off mechanism of residue 35 in framework region 2 of VHH antibodies with β‐hairpin CDR3

Protein Science
Single‐domain VHH antibodies are promising therapeutic and diagnostic tools. The third complementarity‐determining region (CDR3) is usually the most critical region for antigen recognition by VHH antibodies.
Koichi Yamamoto, S. Nagatoishi, Ryo Matsunaga, Makoto Nakakido, Daisuke Kuroda, Kouhei Tsumoto   +5 more
semanticscholar   +1 more source

Expression of VHHs in Saccharomyces cerevisiae

2012
The production of VHHs in microorganisms is relatively straightforward, however the amount of VHH produced per volume unit can vary substantially from hardly detectable to hundreds of milligrams per liter. Expression in Escherichia coli is more commonly used at initial research phase, since production of VHHs for large-scale application in E.
Andrea, Gorlani, Hans, de Haard, Theo, Verrips   +2 more
openaire   +2 more sources

Evaluation of an anti-CD3 VHH and construction of an anti-CD3/anti-EGFR bispecific tandem VHH as a cancer cell targeting drug construct

Biochemistry and Biophysics Reports
Recently, the development of T-cell engager cancer therapeutics, consisting of anticancer and anti-T-cell antibody parts to engage the T-cell to the cancer site, has gained interest.
Takuya Asanuma, Peiwei Ding, Yuki Kato, Takeshi Nakanishi, R. Asano, Koki Makabe   +5 more
semanticscholar   +1 more source

Engineering a Low-Immunogenic Mirror-Image VHH against Vascular Endothelial Growth Factor.

ACS Chemical Biology
Immunogenicity is a major caveat of protein therapeutics. In particular, the long-term administration of protein therapeutic agents leads to the generation of antidrug antibodies (ADAs), which reduce drug efficacy while eliciting adverse events.
Keisuke Aoki, Katsuaki Higashi, Sakiho Oda, Asako Manabe, Kayuu Maeda, Jyoji Morise, S. Oka, S. Inuki, Hiroaki Ohno, Shinya Oishi, Motohiro Nonaka   +10 more
semanticscholar   +1 more source

Production of Designer VHH-Based Antibodies in Plants

2022
Simplified monoclonal antibodies can be produced by fusing a VHH or nanobody, derived from camelid heavy-chain-only antibodies to the Fc domain of either IgG (VHH-IgG), IgA (VHH-IgA), or IgY (VHH-IgY). These recombinant antibodies are encoded by a single gene and their production can be easily scaled up in plants.
openaire   +2 more sources